Concepedia

Publication | Open Access

Clinical and Biomarker Results from Phase I/II Study of PI3K Inhibitor Alpelisib plus Nab-paclitaxel in HER2-Negative Metastatic Breast Cancer

DOIFull Paper Access

82

Citations

29

References

2021

Year

Priyanka Sharma, Vandana G. Abramson, Anne O’Dea, Lauren Nye, Ingrid A. Mayer, Harsh B. Pathak, Marc Hoffmann, Shane R. Stecklein, Manana Elia, Sharon L. Lewis,
Clinical Cancer Research

Abstract

The alpelisib plus nab-paclitaxel combination was well tolerated and shows encouraging efficacy, especially in patients with <i>PIK3CA</i>-mutated tumor/ctDNA. The impact of metabolic status on response to this combination merits further investigation.

References

YearCitations

Page 1